Several other equities research analysts have also issued reports on RYTM. Zacks Investment Research lowered Rhythm Pharmaceuticals from a hold rating to a sell rating in a research note on Wednesday, July 17th. LADENBURG THALM/SH SH reaffirmed a buy rating and set a $43.00 price target on shares of Rhythm Pharmaceuticals in a research note on Monday, September 9th. Stifel Nicolaus reaffirmed a buy rating and set a $34.00 price target on shares of Rhythm Pharmaceuticals in a research note on Monday, July 29th. Canaccord Genuity began coverage on Rhythm Pharmaceuticals in a research note on Monday, July 8th. They set a buy rating and a $35.00 price target for the company. Finally, ValuEngine raised Rhythm Pharmaceuticals from a hold rating to a buy rating in a research note on Thursday, August 1st. Two equities research analysts have rated the stock with a sell rating and six have issued a buy rating to the stock. Rhythm Pharmaceuticals has a consensus rating of Buy and a consensus price target of $38.80.
Shares of RYTM stock opened at $24.51 on Wednesday. The company has a quick ratio of 7.80, a current ratio of 7.80 and a debt-to-equity ratio of 0.02. The business has a 50-day moving average price of $21.56 and a two-hundred day moving average price of $24.20. Rhythm Pharmaceuticals has a 12-month low of $18.00 and a 12-month high of $32.62.
Hedge funds have recently modified their holdings of the business. Point72 Hong Kong Ltd bought a new stake in Rhythm Pharmaceuticals during the second quarter worth about $31,000. Marshall Wace North America L.P. purchased a new position in shares of Rhythm Pharmaceuticals in the first quarter worth about $33,000. Bank of Montreal Can increased its holdings in shares of Rhythm Pharmaceuticals by 194,200.0% in the second quarter. Bank of Montreal Can now owns 1,943 shares of the company’s stock worth $43,000 after buying an additional 1,942 shares during the period. BNP Paribas Arbitrage SA increased its holdings in shares of Rhythm Pharmaceuticals by 105,433.3% in the first quarter. BNP Paribas Arbitrage SA now owns 3,166 shares of the company’s stock worth $87,000 after buying an additional 3,163 shares during the period. Finally, Tiff Advisory Services Inc. purchased a new position in shares of Rhythm Pharmaceuticals in the first quarter worth about $217,000. 90.58% of the stock is owned by hedge funds and other institutional investors.
Rhythm Pharmaceuticals Company Profile
Rhythm Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of rare genetic disorders that result in life-threatening metabolic disorders. The company's lead product candidate is setmelanotide, a melanocortin-4 receptor agonist peptide, which is in Phase III clinical trials to treat pro-opiomelanocortin (POMC) and leptin receptor deficiency obesity, and Bardet-Biedl and Alström syndrome; and is in Phase II clinical trials for treating POMC heterozygous deficiency obesity and POMC epigenetic disorders.
Featured Article: What are some reasons analysts would give stocks a buy rating?
Receive News & Ratings for Rhythm Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rhythm Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.